

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHANGE OF CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

THE BOARD ANNOUNCES THAT:

Mr. Chiu has tendered his resignation as the Chief Financial Officer and the Company Secretary with effect from 6 April 2018 and has also been re-designated as a senior adviser of the Company regarding merger and acquisition issues, to provide advice for acquisitions of the Group.

The Board has appointed Mr. Wang and Mr. Tong as the Chief Financial Officer and the Company Secretary respectively, with effect from 6 April 2018.

The board of directors (the “**Board**”) of China NT Pharma Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Chiu Yu Kang (“**Mr. Chiu**”) has tendered his resignation as the chief financial officer (the “**Chief Financial Officer**”) and the company secretary (the “**Company Secretary**”) of the Company with effect from 6 April 2018. Mr. Chiu has also been re-designated as a senior adviser of the Company regarding merger and acquisition issues, to provide advice for acquisitions of the Group.

Mr. Chiu has confirmed that he has no disagreement with the Board and there are no matters that need to be brought to the attention of the shareholders of the Company.

In addition, the Board is pleased to announce that Mr. Wang Fei (“**Mr. Wang**”) and Mr. Tong Ka Kin Kenneth (“**Mr. Tong**”) have been appointed as the Chief Financial Officer and the Company Secretary respectively, with effect from 6 April 2018.

Mr. Wang, aged 41, joined the Company as the Chief Financial Officer with effect from 6 April 2018 and is responsible for the Group's strategic planning, corporate finance activities, overseeing of financial reporting and investor relations matters.

Mr. Wang is a Chinese certified public accountant, and has accumulated nearly 20 years of extensive experience in audit, accounting and financial management.

Before joining the Company, Mr. Wang worked in AstraZeneca, an international pharmaceutical company, as the chief financial officer of China operation. He was also an independent director Xinjiang Tianye Co., of a company whose A shares were listed on the Shanghai Stock Exchange from March 2013 to October 2016 and a director of Yanchuang Applied Materials (Ganzhou) Inc. Ltd, a company listed on National Equities Exchange and Quotations from October 2016 to November 2017. Mr. Wang graduated from Xinjiang University of Finance and Economics majoring in corporate finance management in 1999 and obtained from Shanghai Jiao Tong University and Euromed Marseille Ecole de Management a master degree majoring in business administration in 2012.

Mr. Tong, aged 32, joined the Company as the Company secretary with effect from 6 April 2018 and is responsible for company secretarial duties of the Group.

Mr. Tong is an associate member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators since 2016. He has accumulated more than 10 years of experience in audit, accounting and financial management.

Before joining the Company, Mr. Tong had worked for various international well-known accounting firms from 2007 to 2016. Mr. Tong graduated from The City University of Hong Kong with a bachelor degree in business administration in 2007, and obtained a master degree in corporate governance from the Hong Kong Polytechnic University in 2015.

The Board would like to extend its welcome to Mr. Wang and Mr. Tong for joining the Company and its gratitude to Mr. Chiu for his contribution to the Company during his tenure of office.

By order of the Board
China NT Pharma Group Company Limited
Ng Tit
Chairman

Hong Kong, 6 April 2018

As at the date of this announcement, the executive directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive directors of the Company are Dr. Qian Wei and Ms. Lou Jianying; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tze Shan Hailson Yu and Dr. Lap-Chee Tsui.